Member of the Association of American Physicians
His main research concerns Internal medicine, Immunology, Acquired immunodeficiency syndrome, Tuberculosis and Viral disease. His Internal medicine research incorporates themes from Pyrazinamide, Surgery and Ethambutol. His study in Immunology is interdisciplinary in nature, drawing from both Disease, Retrospective cohort study and Risk factor.
His Acquired immunodeficiency syndrome research is multidisciplinary, incorporating perspectives in Health care, Pharmacotherapy, Viral load and Cohort study. His Tuberculosis research includes themes of Moxifloxacin and Chemoprophylaxis. His Viral disease research integrates issues from Immunopathology and Pneumonia.
Richard E. Chaisson spends much of his time researching Tuberculosis, Internal medicine, Immunology, Acquired immunodeficiency syndrome and Surgery. His work carried out in the field of Tuberculosis brings together such families of science as Incidence, Pediatrics and Disease. His research in Internal medicine focuses on subjects like Pyrazinamide, which are connected to Ethambutol.
As part of the same scientific family, Richard E. Chaisson usually focuses on Immunology, concentrating on Regimen and intersecting with Intensive care medicine. His study looks at the intersection of Acquired immunodeficiency syndrome and topics like Viral disease with Immunopathology. The study incorporates disciplines such as Rifapentine, Latent tuberculosis and Chemoprophylaxis in addition to Isoniazid.
His primary areas of investigation include Tuberculosis, Internal medicine, Rifapentine, Isoniazid and Regimen. The Tuberculosis study combines topics in areas such as Clinical trial, Randomized controlled trial, Intensive care medicine, Disease and Pediatrics. His Internal medicine research focuses on Adverse effect in particular.
His work in Isoniazid covers topics such as Pharmacokinetics which are related to areas like Interquartile range and Efavirenz. Viral load is a subfield of Immunology that Richard E. Chaisson investigates. Many of his studies involve connections with topics such as Logistic regression and Immunology.
The scientist’s investigation covers issues in Tuberculosis, Internal medicine, Immunology, Disease and Mycobacterium tuberculosis. The various areas that Richard E. Chaisson examines in his Tuberculosis study include Regimen, Cause of death, Obstetrics, Coinfection and Pharmacology. He studies Internal medicine, namely Randomized controlled trial.
Richard E. Chaisson combines subjects such as Acute Retroviral Syndrome, Antiretroviral therapy and Scabies with his study of Immunology. His research integrates issues of Tuberculosis diagnosis and Environmental health in his study of Disease. The concepts of his Mycobacterium tuberculosis study are interwoven with issues in Increased risk, Acquired immunodeficiency syndrome, Transmission, Global health and Airborne disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study
Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka.
PLOS ONE (2015)
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
Payam Nahid;Susan E. Dorman;Narges Alipanah;Pennan M. Barry.
Clinical Infectious Diseases (2016)
Natural history of HIV infection in the era of combination antiretroviral therapy.
Richard D. Moore;Richard E. Chaisson.
USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
David Lanier;Neil Schram;Ellen Cooper;Kenneth A. Freedberg.
Clinical Infectious Diseases (1995)
Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDS
Stephen D. Nightingale;D. William Cameron;Fred M. Gordin;Paul M. Sullam.
The New England Journal of Medicine (1993)
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes
Jean B. Nachega;Michael Hislop;David W. Dowdy;Richard E. Chaisson.
Annals of Internal Medicine (2007)
Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community
Richard D. Moore;David Stanton;Ramana Gopalan;Richard E. Chaisson.
The New England Journal of Medicine (1994)
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa.
Jean B Nachega;Michael Hislop;Hoang Nguyen;David W Dowdy.
Journal of Acquired Immune Deficiency Syndromes (2009)
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
Jonathan E Golub;Valeria Saraceni;Solange C Cavalcante;Antonio G Pacheco.
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Eric L. Nuermberger;Tetsuyuki Yoshimatsu;Sandeep Tyagi;Richard J. O'Brien.
American Journal of Respiratory and Critical Care Medicine (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: